Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
700 participants
OBSERVATIONAL
2022-10-04
2028-04-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The registry will capture data on participants; demographic, clinical characteristics (including biomarker data), treatment patterns, and effectiveness and safety outcomes for advanced NSCLC with mesenchymal-epithelial transition exon 14 (METex14) participants treated with systemic therapy.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Advanced Non-small Cell Lung Cancer with METex14 skipping alterations
Participants diagnosed with advanced NSCLC and who receive available therapies in routine clinical practice setting will be part of this registry. Data will be collected routinely from the point of enrollment of a participants into the registry until death, loss to follow-up (drop-out), subsequent enrollment into a clinical trial, or end of data collection period for the registry.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants with advanced stage (stages IIIB-IV) NSCLC (all histologies) and Confirmed METex14 skipping alterations (by valid assay)
* Participants who are starting or are already being treated with systemic therapy
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Responsible
Role: STUDY_DIRECTOR
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Holy Cross Health
Fort Lauderdale, Florida, United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Klinikum Klagenfurt Am Woerthersee
Klagenfurt, , Austria
Klinik Floridsdorf
Vienna, , Austria
AZ Delta
Roeselare, , Belgium
AZ Nikolaas
Sint-Niklaas, , Belgium
Ottawa Hospital General Campus
Ottawa, , Canada
Princess Margaret Cancer Centre
Toronto, , Canada
FN Olomouc
Olomouc, , Czechia
University Hospital Na Bulovce
Prague, , Czechia
University Hospital of Tampere
Tampere, , Finland
Turun Yliopistollinen Keskussairaala
Turku, , Finland
Centre Hospitalier de Cholet
Cholet, , France
CHRU Lille
Lille, , France
Hôpital du Scorff
Lorient, , France
Centre Leon Berard
Lyon, , France
Hospital Tenon & University Paris 6
Paris, , France
Institut Curie - Centre de Lutte Contre le Cancer (CLCC)
Paris, , France
CHU de Toulouse Hopital Larrey
Toulouse, , France
Klinikum Chemnitz GmbH
Chemnitz, , Germany
KKH Grosshansdorf GmbH
Großhansdorf, , Germany
Thoraxklinik-Heidelberg gGmbH
Heidelberg, , Germany
Klinik Löwenstein GmbH
Löwenstein, , Germany
Haemek Medical Center
Afula, , Israel
Assuta Ashdod Medical Center
Ashdod, , Israel
Bnei-Zion Medical Center
Haifa, , Israel
Carmel Medical Center
Haifa, , Israel
Rambam Medical Center - PPDS
Haifa, , Israel
Shaare Zedek Medical Center
Jerusalem, , Israel
Rabin Medical Center Oncology Beilinson Campus
Petah Tikva, , Israel
Chaim Sheba Medical Center
Ramat Gan, , Israel
Tel Aviv Sourasky Medical Center
Tel Aviv, , Israel
Istituto Europeo di Oncologia
Milan, , Italy
Istituto Nazionale Dei Tumori
Milan, , Italy
AOU dell'Università degli Studi della Campania Luigi Vanvitelli
Napoli, , Italy
I.F.O. Istituto Nazionale Tumori Regina Elena IRCCS
Rome, , Italy
Azienda Sanitaria Ospedaliera S Luigi Gonzaga
Torino, , Italy
Ospedale di Circolo
Varese, , Italy
VU Medisch Centrum
Amsterdam, , Netherlands
Universitair Medisch Centrum Groningen - Department of Medical Oncology
Groningen, , Netherlands
Leiden University Medical Center
Leiden, , Netherlands
Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria
Lisbon, , Portugal
Centro Hospitalar do Porto E.P.E. Hospital de Santo António
Porto, , Portugal
Instituto Portugues de Oncologia Do Porto Francisco Gentil Epe - PPDS
Porto Covo, , Portugal
Clinica Tres Torres
Barcelona, , Spain
Institut Universitari Dexeus-Quiron - Servei d oncologia medica - Institut Oncologic Dr. Rosell
Barcelona, , Spain
Complejo Hospitalario Universitario Insular-Materno Infantil
Las Palmas de Gran Canaria, , Spain
Centro Integral Oncologico Clara Campa
Madrid, , Spain
Centro Oncologico MD Anderson
Madrid, , Spain
Hospital Regional Universitario de Malaga - Hospital General
Málaga, , Spain
Hospidal Universitario Ntra. Sra. De Valme
Seville, , Spain
Hospital Universitario Virgen Macarena
Seville, , Spain
Hospital Universitari i Politecnic La Fe de Valencia
Valencia, , Spain
Universitetssjukhuset i Linköping
Linköping, , Sweden
Bedford General Hospital
Bedford, , United Kingdom
Birmingham Heartlands Hospital
Birmingham, , United Kingdom
Royal Bournemouth Hospital
Bournemouth, , United Kingdom
The Royal Marsden Hospital
Chelsea, , United Kingdom
Royal Surrey County Hospital
Guildford, , United Kingdom
Northwick Park Hospital
Harrow, , United Kingdom
Clatterbridge Cancer Centre - Liverpool
Liverpool, , United Kingdom
Charing Cross Hospital
London, , United Kingdom
Preston Hospital
Preston, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Thomas M, Christopoulos P, Iams WT, Mazieres J, Cortot AB, Peled N, Minuti G, Smit EF, Audhuy F, Berghoff K, Eggleton SP, Fries F, Hildenbrand M, Liu P, Mahmoudpour SH, Menzel C, Oksen D. MOMENT registry: Patients with advanced non-small-cell lung cancer harboring MET exon 14 skipping treated with systemic therapy. J Comp Eff Res. 2025 Feb;14(2):e240127. doi: 10.57264/cer-2024-0127. Epub 2025 Jan 21.
Related Links
Access external resources that provide additional context or updates about the study.
Trial Awareness and Transparency website
US Medical Information website, Medical Resources
Medical Information Location Map - Med Info Contacts
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS200095_0050
Identifier Type: -
Identifier Source: org_study_id